Inspiring Colorado Mom Crosses The Finish Line

 Inspiring Colorado Mom Crosses The Finish Line

NASHVILLE, Tenn. (September 11, 2018) -  Nine months after Gil Schaenzle lost her only child, 21 year old daughter Anna Rose to neuroendocrine (NET) cancer, the same complicated disease that recently ended the life of Aretha Franklin (Queen of Soul), Gil carried on with her and her daughter's mission and ran in 50 national parks across the United States. The demanding pursuit in honor of Anna was designed to raise awareness to an often times misdiagnosed form of cancer.  Clutching Anna's teddy bear throughout every run, Gil crossed the finish line last month for the final time at Denver's Rocky Mountain National Park - the same national park where she and husband Fred used to take Anna as a small child.  Note:  Nine months became a significant measure in Gil's life; she carried Anna for nine months, Anna's illness was nine months from diagnosis to her passing, and Gil carried out the National Park Run in nine months time.

Neuroendocrine (Net) Cancer Patients Get No R-E-S-P-E-C-T 

Neuroendocrine (Net) Cancer Patients Get No R-E-S-P-E-C-T 

NASHVILLE, Tenn. (August 30, 2018) --  Seven years after Apple co-founder Steve Jobs passed, the Neuroendocrine cancer community still gets "no respect."  As fans pay their respects to the Queen of Soul Aretha Franklin this week, the need for Neuroendocrine (NET) cancer awareness is heightened as her physician, Dr. Philip A. Philip, confirms her correct diagnosis--pancreatic neuroendocrine tumors, commonly referred to as pNETs. Many media outlets only reported "pancreatic cancer" and gave statistics that do not apply for pNETs.  "Pancreatic cancer of the Neuroendocrine type," as reported by Franklin's publicist, is a completely different disease than the typical and more common pancreatic cancer (adenocarcinoma). Franklin's physician, Dr. Philip shared, "The only thing they have in common is they both arise from the pancreas."  When the media does not get it right in the case of a beloved well known public icon, it can have a serious impact on the diagnosed and undiagnosed patient

Exemplary And Inspiring Mom Finishes 50 National Park Runs With Half Marathon In Denver's Rocky Mountain National Park

Exemplary And Inspiring Mom Finishes 50 National Park Runs With Half Marathon In Denver's Rocky Mountain National Park

NASHVILLE, Tenn. (July 31, 2018) - Gil Schaenzle will cross the finish line completing her nine month long mission, at Denver's Rocky Mountain National Park this Friday, August 4 - the same national park that she and husband Fred used to take their daughter as a small child.  After losing her only child Anna Rose to NET (neuroendocrine cancer), Schaenzle decided she would cope with her life’s biggest challenge by following through on a plan that she and her daughter designed together and to run in 50 national parks across the U.S. to help raise awareness for one of the most misdiagnosed forms of cancer.  

Gil Schaenzle Honors Daughter And Raises Awareness For Net Cancer

Gil Schaenzle Honors Daughter And Raises Awareness For Net Cancer

NASHVILLE, Tenn. (April 18, 2018) - When Gil Schaenzle lost her only child, 21 year old daughter Anna Rose on March 26, 2017 to a form of cancer called Neuroendocrine tumors (NETs), she came up with a way that would not only help nuture her broken heart, but also celebrate her daughter’s life while raising awareness, funding and hope to this misdiagnosed disease.  Schaenzle is running in 50 U.S. National Parks throughout the contiguous states.  

Gil Schaenzle Honors Daughter and Raises Awareness For Net Cancer

Gil Schaenzle Honors Daughter and Raises Awareness For Net Cancer

NASHVILLE, Tenn. (October 16, 2017) -- When Gil Schaenzle lost her only child, 21 year old daughter Anna Rose earlier this year to Neuroendocrine tumors (NETs), the same complicated disease that ended the life of Apple co-founder Steve Jobs, she wanted to come up with an idea that would allow her to not only celebrate her daughter’s life, but also raise awareness, funding and hope for the rare disease.